159 related articles for article (PubMed ID: 10784228)
1. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
Whitelaw DC; Clark PM; Smith JM; Nattrass M
Diabet Med; 2000 Mar; 17(3):225-9. PubMed ID: 10784228
[TBL] [Abstract][Full Text] [Related]
2. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
3. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
[TBL] [Abstract][Full Text] [Related]
5. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Gribble FM; Manley SE; Levy JC
Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
[TBL] [Abstract][Full Text] [Related]
7. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
Hazama Y; Matsuhisa M; Ohtoshi K; Gorogawa S; Kato K; Kawamori D; Yoshiuchi K; Nakamura Y; Shiraiwa T; Kaneto H; Yamasaki Y; Hori M
Diabetes Res Clin Pract; 2006 Mar; 71(3):251-5. PubMed ID: 16214255
[TBL] [Abstract][Full Text] [Related]
9. Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
Fonseca VA; Kelley DE; Cefalu W; Baron MA; Purkayastha D; Nestler JE; Hsia S; Gerich JE
Metabolism; 2004 Oct; 53(10):1331-5. PubMed ID: 15375790
[TBL] [Abstract][Full Text] [Related]
10. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
Barnett AH; Anderson DM; Shelley S; Morgan R; Owens DR
Diabetes Obes Metab; 2004 Mar; 6(2):104-13. PubMed ID: 14746575
[TBL] [Abstract][Full Text] [Related]
12. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
13. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
14. Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
Lindsay JR; McKillop AM; Mooney MH; O'Harte FP; Flatt PR; Bell PM
Diabetes Res Clin Pract; 2003 Sep; 61(3):167-73. PubMed ID: 12965106
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
[TBL] [Abstract][Full Text] [Related]
16. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
[TBL] [Abstract][Full Text] [Related]
17. Restoring post-prandial insulin release in type 2 diabetes.
Andrews J
Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
[TBL] [Abstract][Full Text] [Related]
18. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue.
Uchino H; Niwa M; Shimizu T; Nishiyama K; Kawamori R
Endocr J; 2000 Oct; 47(5):639-41. PubMed ID: 11200947
[TBL] [Abstract][Full Text] [Related]
19. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
[TBL] [Abstract][Full Text] [Related]
20. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
Li J; Tian H; Li Q; Wang N; Wu T; Liu Y; Ni Z; Yu H; Liang J; Luo R; Li Y; Huang L
Diabetes Obes Metab; 2007 Jul; 9(4):558-65. PubMed ID: 17587398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
